Regulators Exchange Info On COVID-19 Vaccines, EU Urges Pooling Resources
WHO Will Start SOLIDARITY Trial Of Untested Treatments
Executive Summary
Regulators are trying to keep sight of the bigger picture amidst disparate efforts to develop potential treatments and vaccines for the coronavirus outbreak. The World Health Organization and EU regulators are concerned that small individual studies may not be in the best interests of patients and are suggesting pooling resources.
You may also be interested in...
Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
COVID-19 Vaccines: Global Regulators Define Preclinical Data Requirements
Regulators held a virtual meeting to agree on the type and extent of preclinical data needed to inform the clinical development of vaccines for COVID-19.
EU Urges Sponsors To Assess COVID-19 Impact Before Starting New Trials
New EU guidance on managing clinical trials in the context of COVID-19 requires sponsors to critically assess the feasibility of starting a new clinical trial or including new participants in an ongoing trial. A separate survey indicates that patient willingness to participate in new trials has dramatically declined due to the pandemic.